Our Story

At Impax Laboratories we are following a growth-oriented strategy to become a leader in the development, manufacturing and marketing of specialty prescription pharmaceutical products.

Strategic Merger

On December 14, 1999, Global Pharmaceutical Corporation and privately held Impax Pharmaceuticals, Inc. completed a reverse merger, forming a new organization called Impax Laboratories, Inc. The merger combined the advanced drug delivery systems developed by Impax Pharmaceuticals through its research and development capabilities with Global Pharmaceutical’s sales, marketing and distribution capabilities.


Drug Applications

The synergy created by the merger provided the foundation for the current and future success of the organization. Since 1999, Impax Laboratories consistently files abbreviated new drug applications with the Food and Drug Administration (FDA) annually, and has received tentative and final approval from the FDA for numerous generic products.

We are also developing proprietary branded products for unmet needs in the treatment of Central Nervous System (CNS) disorders. We have one new drug application pending at the FDA for the treatment of symptomatic Parkinson’s disease.


Marketing Partnerships and Business Development

Where strategically appropriate, the Company has developed marketing partnerships to fully leverage its technology platform in order to maximize product revenues and profitability. Impax Laboratories also has two marketing divisions of its own for its products. Its Global Pharmaceuticals division sells generic products, while branded products are marketed through the Impax Pharmaceuticals division.

We are also pursuing generic and brand partnership and business development (M&A) opportunities. Global Pharmaceuticals is looking at opportunities to acquire products, technologies or companies with strategic value mainly in the alternative dosage area, such as injectables, creams and ointments, inhalers or patches. Impax Pharmaceuticals is searching for external growth opportunities with a focus on neurology and psychiatry products.